Auspex Pharmaceuticals, Inc. 4
4 · Auspex Pharmaceuticals, Inc. · Filed Dec 23, 2014
Insider Transaction Report
Form 4
Stamler David A
Chief Medical Officer
Transactions
- Sale
Common Stock
2014-12-22$53.28/sh−1,560$83,118→ 2,083 total - Exercise/Conversion
Stock Option (right to buy)
2014-12-22−2,660→ 28,274 totalExercise: $0.90Exp: 2021-03-10→ Common Stock (2,660 underlying) - Sale
Common Stock
2014-12-22$53.92/sh−1,100$59,316→ 983 total - Exercise/Conversion
Common Stock
2014-12-22$0.90/sh+2,660$2,394→ 3,643 total
Footnotes (5)
- [F1]Includes 591 shares purchased through the Company's 2014 Employee Stock Purchase Plan ("ESPP") on May 20, 2014, and 392 shares purchased through the ESPP on November 20, 2014.
- [F2]The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 23, 2014.
- [F3]This transaction was executed in multiple trades at prices ranging from a low of $52.80 to a high of $53.64. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]This transaction was executed in multiple trades at prices ranging from a low of $53.71 to a high of $54.065. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F5]The original option grant to purchase 30,934 shares of common stock (split-adjusted) is subject to monthly vesting over a four-year period beginning on February 15, 2011.